Zydus Gets CDSCO Panel Nod To Study Follitropin alfa
New Delhi: The drug major Zydus has got a green signal from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct Phase IV study of recombinant human follicle-stimulating hormone, Follitropin alfa.
Follitropin alfa injection is also used as a fertility medicine to help men with low sperm counts produce more sperm. Treatment with human chorionic gonadotropin should come before treatment with follitropin alfa.
Follitropin alpha (recombinant human follicle-stimulating hormone; follitropin alfa) is a recombinant form of follicle-stimulating hormone (FSH), an endogenous gonadotrophin.
FSH binds to the follicle-stimulating hormone receptor which is a G-coupled transmembrane receptor. The binding of the FSH to its receptor seems to induce phosphorylation and activation of the PI3K (Phosphatidylinositol-3-kinase) and Akt signalling pathway, which is known to regulate many other metabolic and related survival/maturation functions in cells.
At the recent SEC meeting for Reproductive and Urology held on 30th November 2022, the expert panel reviewed the proposal presented by the drug major Zydus to conduct Phase IV clinical trial for the Follitropin alfa (rFSH) Injection in multidose pre-filled glass cartridges (300 IU, 450 IU, 900 IU) or single-use Vial (75 IU).
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.